MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
New Findings Highlight MIRA-55’s Potent CB2 Activation With More Than 500-Fold Separation From Measured Mu, Delta, and Kappa Opioid Receptor Interactions MIRA-55’s Differentiated Profile Combines CB2/CB1 Activity, Brain Penetration, and Distinct Signaling

Follow